These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9828233)

  • 1. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.
    Xiong X; Flores C; Yang H; Toole JJ; Gibbs CS
    Hepatology; 1998 Dec; 28(6):1669-73. PubMed ID: 9828233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance.
    Xiong X; Yang H; Westland CE; Zou R; Gibbs CS
    Hepatology; 2000 Jan; 31(1):219-24. PubMed ID: 10613749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
    Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
    J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
    Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
    J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
    Qi X; Xiong S; Yang H; Miller M; Delaney WE
    Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
    Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
    Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
    Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
    J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.
    Villet S; Pichoud C; Billioud G; Barraud L; Durantel S; Trépo C; Zoulim F
    J Hepatol; 2008 May; 48(5):747-55. PubMed ID: 18331765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
    Arslan U; Ural O; Findik D
    Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
    Suzuki F; Kumada H; Nakamura H
    J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.
    Ono-Nita SK; Kato N; Shiratori Y; Lan KH; Yoshida H; Carrilho FJ; Omata M
    J Clin Invest; 1999 Jun; 103(12):1635-40. PubMed ID: 10377169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
    Cho JH; Cheong JY; Kang JK; Park JS; Lee MH; Lim NK; Hong SP; Kim SO; Yoo WD; Cho SW
    Korean J Hepatol; 2008 Mar; 14(1):58-66. PubMed ID: 18367858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.
    Yang H; Westland CE; Delaney WE; Heathcote EJ; Ho V; Fry J; Brosgart C; Gibbs CS; Miller MD; Xiong S
    Hepatology; 2002 Aug; 36(2):464-73. PubMed ID: 12143057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
    Perrillo R; Schiff E; Yoshida E; Statler A; Hirsch K; Wright T; Gutfreund K; Lamy P; Murray A
    Hepatology; 2000 Jul; 32(1):129-34. PubMed ID: 10869300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
    J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance.
    Zoulim F
    Semin Liver Dis; 2002; 22 Suppl 1():23-31. PubMed ID: 12447726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.